DUPILUMAB REDUCES SEVERE ASTHMA EXACERBATION RATE AND IMPROVES LUNG FUNCTION REGARDLESS OF AGE AT ONSET OF ASTHMA: THE LIBERTY ASTHMA QUEST STUDY.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Subject Terms:
    • Abstract:
      In the phase 3 LIBERTY ASTHMA QUEST study (NCT02414854), add-on dupilumab 200 mg or 300 mg every 2 weeks (q2w) vs placebo significantly reduced asthma exacerbation rates and improved pre-bronchodilator forced expiratory volume in 1 second (FEV1) in patients with uncontrolled moderate-to-severe asthma. B RESULTS: b At baseline, compared with patients with EOA, patients with LOA had a lower mean pre-bronchodilator FEV1 (1.52 L vs 1.88 L) and fewer LOA patients had an ongoing atopic condition (71.1% vs 86.6%). [Extracted from the article]
    • Abstract:
      Copyright of CHEST is the property of American College of Chest Physicians and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
    • ISSN:
      0012-3692
    • Accession Number:
      10.1016/j.chest.2019.08.870
    • Accession Number:
      139141769
  • Citations
    • ABNT:
      CASTRO, M. et al. Dupilumab Reduces Severe Asthma Exacerbation Rate and Improves Lung Function Regardless of Age at Onset of Asthma: The Liberty Asthma Quest Study. CHEST, [s. l.], v. 156, p. A936–A939, 2019. DOI 10.1016/j.chest.2019.08.870. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=hch&AN=139141769. Acesso em: 2 dez. 2020.
    • AMA:
      Castro M, Hanania N, Quirce S, et al. Dupilumab Reduces Severe Asthma Exacerbation Rate and Improves Lung Function Regardless of Age at Onset of Asthma: The Liberty Asthma Quest Study. CHEST. 2019;156:A936-A939. doi:10.1016/j.chest.2019.08.870
    • APA:
      Castro, M., Hanania, N., Quirce, S., Sher, L., Maspero, J., Rice, M., Djandji, M., Ballard, M., Rowe, P., Deniz, Y., & Teper, A. (2019). Dupilumab Reduces Severe Asthma Exacerbation Rate and Improves Lung Function Regardless of Age at Onset of Asthma: The Liberty Asthma Quest Study. CHEST, 156, A936–A939. https://doi.org/10.1016/j.chest.2019.08.870
    • Chicago/Turabian: Author-Date:
      Castro, Mario, Nicola Hanania, Santiago Quirce, Lawrence Sher, Jorge Maspero, Megan Rice, Michel Djandji, et al. 2019. “Dupilumab Reduces Severe Asthma Exacerbation Rate and Improves Lung Function Regardless of Age at Onset of Asthma: The Liberty Asthma Quest Study.” CHEST 156 (October): A936–39. doi:10.1016/j.chest.2019.08.870.
    • Harvard:
      Castro, M. et al. (2019) ‘Dupilumab Reduces Severe Asthma Exacerbation Rate and Improves Lung Function Regardless of Age at Onset of Asthma: The Liberty Asthma Quest Study’, CHEST, 156, pp. A936–A939. doi: 10.1016/j.chest.2019.08.870.
    • Harvard: Australian:
      Castro, M, Hanania, N, Quirce, S, Sher, L, Maspero, J, Rice, M, Djandji, M, Ballard, M, Rowe, P, Deniz, Y & Teper, A 2019, ‘Dupilumab Reduces Severe Asthma Exacerbation Rate and Improves Lung Function Regardless of Age at Onset of Asthma: The Liberty Asthma Quest Study’, CHEST, vol. 156, pp. A936–A939, viewed 2 December 2020, .
    • MLA:
      Castro, Mario, et al. “Dupilumab Reduces Severe Asthma Exacerbation Rate and Improves Lung Function Regardless of Age at Onset of Asthma: The Liberty Asthma Quest Study.” CHEST, vol. 156, Oct. 2019, pp. A936–A939. EBSCOhost, doi:10.1016/j.chest.2019.08.870.
    • Chicago/Turabian: Humanities:
      Castro, Mario, Nicola Hanania, Santiago Quirce, Lawrence Sher, Jorge Maspero, Megan Rice, Michel Djandji, et al. “Dupilumab Reduces Severe Asthma Exacerbation Rate and Improves Lung Function Regardless of Age at Onset of Asthma: The Liberty Asthma Quest Study.” CHEST 156 (October 2, 2019): A936–39. doi:10.1016/j.chest.2019.08.870.
    • Vancouver/ICMJE:
      Castro M, Hanania N, Quirce S, Sher L, Maspero J, Rice M, et al. Dupilumab Reduces Severe Asthma Exacerbation Rate and Improves Lung Function Regardless of Age at Onset of Asthma: The Liberty Asthma Quest Study. CHEST [Internet]. 2019 Oct 2 [cited 2020 Dec 2];156:A936–9. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=hch&AN=139141769